LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
![Foto de LUIS GONZAGA](/img/nophoto.png)
![Foto de University Hospital of Lausanne](/img/noimage_org.png)
University Hospital of Lausanne
Lausana, SuizaPublicaciones en colaboración con investigadores/as de University Hospital of Lausanne (20)
2024
-
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)
Lung Cancer, Vol. 187
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases
Lung Cancer, Vol. 188
-
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma
European Journal of Cancer, Vol. 207
2023
-
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
ESMO Open, Vol. 8, Núm. 4
-
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10378, pp. 733-746
-
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069
2022
-
Addressing CPI resistance in NSCLC: Targeting TAM receptors to modulate the tumor microenvironment and future prospects
Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 7
-
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487
-
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 10, pp. 1274-1286
2019
-
Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119
2017
-
First-line nivolumab in stage IV or recurrent non-small-cell lung cancer
New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426
-
Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)
Journal of Clinical Oncology
2016
2015
-
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer
Annals of Oncology, Vol. 26, Núm. 8, pp. 1573-1588
2014
-
2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease
Annals of Oncology, Vol. 25, Núm. 8, pp. 1475-1484
-
2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
Annals of Oncology, Vol. 25, Núm. 8, pp. 1462-1474
-
Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer
Annals of Oncology, Vol. 25, Núm. 9, pp. 1681-1690
2013
-
Strategies for improving outcomes in NSCLC: A look to the future
Lung Cancer, Vol. 82, Núm. 3, pp. 375-382
2012
-
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179